サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：癌用モノクローナル抗体の市場規模、シェア、動向分析レポート：タイプ別（キメラ抗体、ヒト化抗体）、用途別（血液癌、乳癌、肺癌）、エンドユーザー別、地域別、セグメント別予測、2022年～2030年
市場調査レポート
商品コード
1114173

癌用モノクローナル抗体の市場規模、シェア、動向分析レポート：タイプ別（キメラ抗体、ヒト化抗体）、用途別（血液癌、乳癌、肺癌）、エンドユーザー別、地域別、セグメント別予測、2022年～2030年

Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Type (Chimeric Antibodies, Humanized Antibodies), By Application (Blood Cancer, Breast Cancer, Lung Cancer), By End-user, By Region, And Segment Forecasts, 2022 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
癌用モノクローナル抗体の市場規模、シェア、動向分析レポート：タイプ別（キメラ抗体、ヒト化抗体）、用途別（血液癌、乳癌、肺癌）、エンドユーザー別、地域別、セグメント別予測、2022年～2030年
出版日: 2022年07月15日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん用モノクローナル抗体市場の成長と動向

グランドビューリサーチ社の最新レポートによると、がんモノクローナル抗体の世界市場規模は2030年までに1597億米ドルに達すると予測されています。

同市場は2022年から2030年にかけてCAGR11.2%で拡大すると予測されています。癌の有病率の増加、堅牢なパイプラインとともに製品の承認が、市場成長を増大させる主な要因となっています。さらに、この分野での研究開発への資金提供の増加が、産業の成長に影響を与えると予想されます。さらに、バイオシミラー市場の活況は、予測期間中にさらに有利な機会を提供するものと思われます。

非小細胞肺がん（NSCLC）は、一般的な肺がんの一種です。転移性NSCLCの場合、診断後5年以上生きられるのはわずか8％程度であり、予後不良の場合がほとんどです。さらに、現時点では、非扁平上皮型非小細胞肺がん患者のほぼ2～4％に見られるHER2変異型非小細胞肺がんの治療に正確に承認されたHER2指向性の治療薬はありません。しかし、この2年間で、主にファーストライン治療において進歩が見られ、かなりのアンメット・メディカル・ニーズが残されています。例えば、2022年4月、第一三共とアストラゼネカは、切除不能なNSCLCの成人患者の治療を目的として、米国でエンヘルトゥの生物製剤承認補足申請（sBLA）の受理を受けました。

モノクローナル抗体の開発は、この3年間、臨床的にも技術研究的にも大きな進展がありました。安全性、特異性、有効性などの利点から、現在では先進的な治療薬として広く受け入れられています。特にがんは、モノクローナル抗体関連の研究開発プログラムの50％近くを占める、最も重要な医薬品応用分野です。

また、2021年6月には、ブリストル・マイヤーズスクイブ社のヤーボイとオプジーボの併用療法が、悪性胸膜中皮腫の患者さんの治療薬として欧州委員会から承認されています。また、2022年6月には、リジェネロン社が、サノフィとリジェネロンの提携によるリブタヨに関するサノフィの株式を購入し、同社が同薬の世界な独占開発・製造・商業化権を獲得する計画を発表しました。さらに、2020年5月、ギリアド・サイエンシズ社とアーカスバイオサイエンス社は、アーカス社のパイプラインにある最近および将来の治療薬候補を共同商業化および共同開発する10年間のパートナーシップを締結しました。アルカスは、現在、3つのモノクローナル抗体で、その範囲内の分子について10の臨床試験を実施しています。

2020年3月の最後の2週間に米国と欧州でCOVID-19が転機を迎えると、その遠大な影響は業界や企業全体で観察され、病院はがんの治療処置を延期または中止し、臨床試験を停止しました。このため、市場の成長はある程度阻害されました。しかし、治療処置が再開されるにつれて、メーカーは2021年後半にビジネスの着実な改善を観察しました。

がんモノクローナル抗体市場レポートハイライト。

製品タイプ別では、マウスモノクローナル抗体の低コスト、入手性、迅速な生産時間などの要因により、ヒト型セグメントが2021年の市場で大きなシェアを占めています。しかし、ヒト型セグメントは、製品承認や製品上市の数の増加により、予測期間中に最も高いCAGRを維持すると予想される

血液がん用途セグメントは、堅牢なパイプラインとともに、血液疾患の有病率の増加により、2021年に大きな収益シェアを占めました。また、肺がんセグメントは予測期間中、最も高いCAGRで拡大する見通しです

2021年には、患者の入院数の急増により、病院セグメントが主要なエンドユーザーセグメントとなりました。また、施設内で革新的な薬物療法を利用できることが、患者の嗜好を後押ししている

2021年の世界市場は、主要な市場プレイヤーの戦略的活動、がん患者の増加、同地域における政府の支援的な取り組みにより、北米が支配的であった

アジア太平洋では、特に先進国や発展途上国の事業体間の国際的および国家的な協力関係の増加により、将来的に市場が大幅に成長すると予想される

目次

第1章 調査手法

  • 情報調達
  • データ分析

第2章 エグゼクティブサマリー

  • 市場のスナップショット

第3章 がんモノクローナル抗体市場の変数、動向、範囲

  • 市場系列の見通し
    • 親会社の市場見通し
    • アンシラリー市場の見通し
  • 浸透と成長の見通しのマッピング
  • 市場セグメンテーションと範囲
  • がんモノクローナル抗体市場分析市場力学
  • 市場促進要因分析
    • 癌の有病率の増加
    • 研究開発への投資の増加
    • 個別化医療に対する嗜好の高まり
  • 市場制約分析
    • モノクローナル抗体治療薬の高コスト
  • 主な機会
    • 活況を呈するバイオシミラー市場
  • がんモノクローナル抗体市場PESTLE分析
  • 業界分析- ポーターズ
  • 主要取引と戦略的提携分析
    • 合弁事業
    • 合併と買収
    • ライセンシングとパートナーシップ
    • 技術提携
    • 戦略的ダイベストメント
  • COVID-19影響分析

第4章 がんモノクローナル抗体市場：セグメント分析、タイプ別、2018年から2030年（10億米ドル）

  • がんモノクローナル抗体市場：タイプ変動分析
  • ヒト化
  • 人間
  • キメラ
  • ネズミ

第5章 がんモノクローナル抗体市場：セグメント分析、アプリケーション別、2018年から2030年（10億米ドル）

  • がんモノクローナル抗体市場：アプリケーションの変動分析
  • 血液がん
  • 乳がん
  • 肺癌
  • メラノーマ
  • 大腸がん
  • 肝臓がん
  • その他

第6章 がんモノクローナル抗体市場：セグメント分析、エンドユーザー別、2018年から2030年（10億米ドル）

  • がんモノクローナル抗体市場：エンドユーザーの変動分析
  • 病院
  • 調査
  • その他

第7章 がんモノクローナル抗体市場：セグメント分析、地域別、2018年から2030年（10億米ドル）

  • がんモノクローナル抗体市場：地域変動分析
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • 中東およびアフリカ（MEA）
    • 南アフリカ
    • サウジアラビア

第8章 競合情勢

  • Vendor Landscape
    • 世界のがんモノクローナル抗体市場：主要企業の市場シェア分析、2021年
  • Company Profiles
    • F. HOFFMANN-LA ROCHE LTD
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • パイプライン分析
      • 戦略的イニシアチブ
    • BRISTOL MYERS SQUIBB CO.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • パイプライン分析
      • 戦略的イニシアチブ
    • MERCK &CO.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • パイプライン分析
      • 戦略的イニシアチブ
    • GLAXOSMITHKLINE PLC
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • パイプライン分析
      • 戦略的イニシアチブ
    • JOHNSON &JOHNSON
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • パイプライン分析
      • 戦略的イニシアチブ
    • AMGEN, INC.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • パイプライン分析
      • 戦略的イニシアチブ
    • NOVARTIS AG
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • パイプライン分析
      • 戦略的イニシアチブ
    • ASTRAZENECA PLC
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • パイプライン分析
      • 戦略的イニシアチブ
    • ELI LILLY AND COMPANY
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • パイプライン分析
      • 戦略的イニシアチブ
    • ABBVIE
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • パイプライン分析
      • 戦略的イニシアチブ
図表

List of Tables

  • TABLE 1 Cancer monoclonal antibodies market - Industry snapshot & key buying criteria
  • TABLE 2 Cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 3 Cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 4 Cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 5 Cancer monoclonal antibodies market, by region, 2018 - 2030 (USD Billion)
  • TABLE 6 North America cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 7 North America cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 8 North America cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 9 U.S. cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 10 U.S. cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 11 U.S. cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 12 Canada cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 13 Canada cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 14 Canada cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 15 Europe cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 16 Europe cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 17 Europe cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 18 U.K. cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 19 U.K. cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 20 U.K. cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 21 Germany cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 22 Germany cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 23 Germany cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 24 France cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 25 France cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 26 France cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 27 Asia Pacific cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 28 Asia Pacific cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 29 Asia Pacific cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 30 Japan cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 31 Japan cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 32 Japan cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 33 China cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 34 China cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 35 China cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 36 India cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 37 India cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 38 India cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 39 Latin America cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 40 Latin America cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 41 Latin America cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 42 Brazil cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 43 Brazil cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 44 Brazil cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 45 Mexico cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 46 Mexico cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 47 Mexico cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 48 MEA cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 49 MEA cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 50 MEA cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 51 South Africa cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 52 South Africa cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 53 South Africa cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 54 Saudi Arabia cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 55 South Abrabia cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 56 South Abrabia cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)

List of Figures

  • FIG. 1 Market Research Process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary Research Pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Value Chain Based Sizing & Forecasting
  • FIG. 6 QFD Modelling For Market Share Assessment
  • FIG. 7 Market summary 2022 (USD Billion)
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Cancer monoclonal antibodies market analysis, 2018 - 2030 (USD Billion)
  • FIG. 11 Cancer monoclonal antibodies market dynamics
  • FIG. 12 Market driver relevance analysis (Current & future impact)
  • FIG. 13 Global pharmaceutical industry, 2014 - 2022 (USD Billion)
  • FIG. 14 Market restraint relevance analysis (Current & future impact)
  • FIG. 15 Key Opportunities
  • FIG. 16 Cancer monoclonal antibodies market PESTEL analysis
  • FIG. 17 Porter's Five Forces Analysis
  • FIG. 18 Cancer monoclonal antibodies market, type outlook key takeaways (USD Billion)
  • FIG. 19 Cancer monoclonal antibodies market: Type movement analysis (USD Billion)
  • FIG. 20 Humanized market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 21 Human market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 20 Chimeric market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 21 Murine market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 22 Cancer monoclonal antibodies market, application outlook key takeaways (USD Billion)
  • FIG. 23 Cancer M monoclonal antibodies market: Therapeutic application movement analysis (USD Billion)
  • FIG. 24 Blood cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 25 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 26 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 27 Melanoma market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 28 Colorectal cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 29 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 30 Other applications market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 31 Cancer monoclonal antibodies market, end-user outlook key takeaways (USD Billion)
  • FIG. 32 Cancer monoclonal antibodies market: End-user movement analysis (USD Billion)
  • FIG. 33 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 34 Research Institutes market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 35 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 36 Regional market place: Key takeaways (USD Billion)
  • FIG. 37 Cancer monoclonal antibodies market: Regional movement analysis (USD Billion)
  • FIG. 38 North America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 39 U.S. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 40 Canada cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 41 Europe cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 42 U.K. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 43 Germany cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 44 France cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 45 Asia Pacific cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 46 Japan cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 47 China cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 48 India cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 49 Latin America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 50 Brazil cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 51 Mexico cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 52 MEA cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 53 South Africa cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 54 Saudi Arabia cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
目次
Product Code: GVR-4-68039-957-1

Cancer Monoclonal Antibodies Market Growth & Trends:

The global cancer monoclonal antibodies market size is expected to reach USD 159.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.2% from 2022 to 2030. The increasing prevalence of cancer, and product approvals along with a robust pipeline are the key factors augmenting the market growth. Furthermore, an increase in funding for R&D in this sector is expected to impact industrial growth. Moreover, the booming biosimilar market will further offer lucrative opportunities during the forecast period.

Non-small Cell Lung Cancer (NSCLC) is a common type of lung cancer. For patients with metastatic NSCLC, the prognosis is mostly poor, as only about 8% will live beyond 5 years after the diagnosis. Moreover, at present, there are no HER2-directed therapies approved precisely for treating HER2-mutant non-small cell lung cancer, which occurs in almost 2-4% of patients with non-squamous NSCLC. However, progress has been made over the last two years, mainly in the first-line setting, leaving a substantial unmet medical need. For instance, in April 2022, Daiichi Sankyo and AstraZeneca received acceptance of supplemental Biologics License Application (sBLA) of Enhertu in the U.S. for treating adult patients with unresectable NSCLC.

The development of monoclonal antibodies has been great both in clinical and technical research applications over the past three years. Given their advantages of safety, specificity, and efficacy, there is now prevalent acceptance of mAbs as advanced therapeutic agents. Cancer is the most dominating and important area of medicinal application, accounting for almost 50% of all monoclonal antibodies-related R&D programs.

In addition, in June 2021, the European Commission approved Bristol Myers Squibb's combination therapy of Yervoy and OPDIVO to treat patients for malignant pleural mesothelioma. In June 2022, Regeneron Pharmaceuticals, Inc. announced its plan to purchase Sanofi's stake in the Sanofi and Regeneron partnership on Libtayo, providing the company with exclusive global development, manufacturing, and commercialization rights to the medicine. Furthermore, in May 2020, Gilead Sciences, Inc. and Arcus Biosciences, Inc. entered into a 10-year partnership to co-commercialize and co-develop recent and future therapeutic candidates in Arcus's pipeline. Arcus has 10 current clinical studies of molecules in its range with three monoclonal antibodies.

As COVID-19 reached a tipping point in the U.S. and Europe during the last two weeks of March 2020, its far-reaching consequences were observed across industries and businesses, with hospitals postponing or canceling treatment procedures for cancer and halting clinical trials. This has hampered the market growth to an extent. However, as treatment procedures resumed, manufacturers observed a steady improvement in business in the second half of 2021.

Cancer Monoclonal Antibodies Market Report Highlights:

  • By type, the humanized segment held a larger share of the market in 2021 owing to factors such as, low cost, availability, and quick production time for mouse monoclonal antibodies. However, the human segment is expected to hold the highest CAGR during the forecast period due to an increase in the number of product approvals and product launches
  • The blood cancer application segment held a significant revenue share in 2021 owing to an increase in the prevalence of hematological disorders along with a robust pipeline. In addition, the lung cancer segment is poised to expand at the highest CAGR during the forecast period
  • In 2021, the hospital segment was the leading end-user segment due to an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in the facility drives the patient preference
  • North America dominated the global market in 2021, due to the strategic activities of key market players, increasing cancer cases, and supportive government efforts in this region
  • In Asia Pacific, the market is expected to grow considerably in the future due to the increasing number of international and national collaborations among entities, especially those in developed and developing countries

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information Procurement
  • 1.2 Data Analysis

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Cancer Monoclonal Antibodies Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Ancillary market outlook
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Market Segmentation & Scope
  • 3.4 Cancer Monoclonal Antibodies Market Analysis Market Dynamics
  • 3.5 Market Driver Analysis
    • 3.5.1 Growing prevalance of cancer
    • 3.5.2 Increasing investement in research and development
    • 3.5.3 Rising preference for personalized medicines
  • 3.6 Market Restraint Analysis
    • 3.6.1 High cost of monoclonal antiobdy therpaeutics
  • 3.7 Key Opportunities
    • 3.7.1 Booming Biosimilar market
  • 3.8 Cancer Monoclonal Antibodies Market - PESTLE analysis
  • 3.9 Industry Analysis - Porter's
  • 3.10 Major Deals & Strategic Alliances Analysis
    • 3.10.1 Joint ventures
    • 3.10.2 Mergers & acquisitions
    • 3.10.3 Licensing & partnership
    • 3.10.4 Technology collaborations
    • 3.10.5 Strategic divestments
  • 3.11 COVID-19 Impact Analysis

Chapter 4 Cancer Monoclonal Antibodies Market: Segment Analysis, by Type, 2018 - 2030 (USD Billion)

  • 4.1 Cancer Monoclonal Antibodies Market: Type Movement Analysis
  • 4.2 Humanized
    • 4.2.1 Humanized Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.3 Human
    • 4.3.1 Human Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.4 Chimeric
    • 4.4.1 Chimeric Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.5 Murine
    • 4.5.1 Murine Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5 Cancer Monoclonal Antibodies Market: Segment Analysis, By Application, 2018 - 2030 (USD Billion)

  • 5.1 Cancer Monoclonal Antibodies Market: Application Movement Analysis
  • 5.2 Blood Cancer
    • 5.2.1 Blood Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.3 Breast Cancer
    • 5.3.1 Breast Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.4 Lung Cancer
    • 5.4.1 Lung Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.5 Melanoma
    • 5.5.1 Melanoma Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.6 Colorectal Cancer
    • 5.6.1 Colorectal Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.7 Liver Cancer
    • 5.7.1 Liver Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.8 Others
    • 5.8.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 6 Cancer Monoclonal Antibodies Market: Segment Analysis, By End-User, 2018 - 2030 (USD Billion)

  • 6.1 Cancer Monoclonal Antibodies Market: End-User Movement Analysis
  • 6.2 Hospitals
    • 6.2.1 Hospitals Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.3 Research Institutes
    • 6.3.1 Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.4 Others
    • 6.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 7 Cancer Monoclonal Antibodies Market: Segment Analysis, By Region, 2018 - 2030 (USD Billion)

  • 7.1 Cancer Monoclonal Antibodies Market: Regional Movement Analysis
  • 7.2 North America
    • 7.2.1 North America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.2.3 Canada
      • 7.2.3.1 Canada cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.3 Europe
    • 7.3.1 Europe cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.3.2 U.K.
      • 7.3.2.1 U.K. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.3.3 Germany
      • 7.3.3.1 Germany cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.3.4 France
      • 7.3.4.1 France cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.4.2 Japan
      • 7.4.2.1 Japan cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.4.3 China
      • 7.4.3.1 China cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.4.4 India
      • 7.4.4.1 India cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.5 Latin America
    • 7.5.1 Latin America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.6 Middle East and Africa (MEA)
    • 7.6.1 MEA cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)

Chapter 8 Competitive Landscape

  • 8.1 Vendor Landscape
    • 8.1.1 Global Cancer Monoclonal Antibody Market: Key Company Market Share Analysis, 2021
  • 8.2 Company Profiles
    • 8.2.1 F. HOFFMANN-LA ROCHE LTD
      • 8.2.1.1 Company overview
      • 8.2.1.2 Financial performance
      • 8.2.1.3 Product benchmarking
      • 8.2.1.4 Pipeline analysis
      • 8.2.1.5 Strategic initiatives
    • 8.2.2 BRISTOL MYERS SQUIBB CO.
      • 8.2.2.1 Company overview
      • 8.2.2.2 Financial performance
      • 8.2.2.3 Product benchmarking
      • 8.2.2.4 Pipeline analysis
      • 8.2.2.5 Strategic initiatives
    • 8.2.3 MERCK & CO.
      • 8.2.3.1 Company overview
      • 8.2.3.2 Financial performance
      • 8.2.3.3 Product benchmarking
      • 8.2.3.4 Pipeline analysis
      • 8.2.3.5 Strategic initiatives
    • 8.2.4 GLAXOSMITHKLINE PLC
      • 8.2.4.1 Company overview
      • 8.2.4.2 Financial performance
      • 8.2.4.3 Product benchmarking
      • 8.2.4.4 Pipeline analysis
      • 8.2.4.5 Strategic initiatives
    • 8.2.5 JOHNSON & JOHNSON
      • 8.2.5.1 Company overview
      • 8.2.5.2 Financial performance
      • 8.2.5.3 Product benchmarking
      • 8.2.5.4 Pipeline analysis
      • 8.2.5.5 Strategic initiatives
    • 8.2.6 AMGEN, INC.
      • 8.2.6.1 Company overview
      • 8.2.6.2 Financial performance
      • 8.2.6.3 Product benchmarking
      • 8.2.6.4 Pipeline analysis
      • 8.2.6.5 Strategic initiatives
    • 8.2.7 NOVARTIS AG
      • 8.2.7.1 Company overview
      • 8.2.7.2 Financial performance
      • 8.2.7.3 Product benchmarking
      • 8.2.7.4 Pipeline analysis
      • 8.2.7.5 Strategic initiatives
    • 8.2.8 ASTRAZENECA PLC
      • 8.2.8.1 Company overview
      • 8.2.8.2 Financial performance
      • 8.2.8.3 Product benchmarking
      • 8.2.8.4 Pipeline analysis
      • 8.2.8.5 Strategic initiatives
    • 8.2.9 ELI LILLY AND COMPANY
      • 8.2.9.1 Company overview
      • 8.2.9.2 Financial performance
      • 8.2.9.3 Product benchmarking
      • 8.2.9.4 Pipeline analysis
      • 8.2.9.5 Strategic initiatives
    • 8.2.10 ABBVIE
      • 8.2.10.1 Company overview
      • 8.2.10.2 Financial performance
      • 8.2.10.3 Product benchmarking
      • 8.2.10.4 Pipeline analysis
      • 8.2.10.5 Strategic initiatives